CCL17 and Alzheimer disease: Consistently with the differences found between healthy controls and patients with AD (Figs 2, 3), SC inflammatory biomarkers IL‐18, CXCL8, VEGF‐A and Flt‐1 showed the strongest associations with barrier function and AD severity, followed by CCL17, CCL22, sICAM‐1 and sVCAM‐1.